Company intelligence / Profile preview
Shanghai PerHum Therapeutics
- Ownership
- Private
- Development stage
- Other
01
Overview
Shanghai PerHum Therapeutics developed first-in-human solid tumor CAR-T products using an AND logic gate design to improve safety by requiring both a tumor antigen and the acidic tumor microenvironment for activation. Interim results in metastatic renal cell carcinoma showed feasibility, safety, and no dose-limiting toxicities. However, all known clinical trials have been terminated or discontinued as of late-2024 due to strategic adjustments.[3][7]
- Therapeutic areas
- Oncology
- Modalities
- CAR-T cell therapiesGene therapiesImmunotherapies
- Industry
- Biotech
02
Drug pipeline
2 assets1 more asset in the full pipeline.
Beyond the preview
Go deeper on Shanghai PerHum Therapeutics.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Shanghai PerHum Therapeutics.